Vaccination with gp160 in HIV.

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2.

Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients.

Effect of a recombinant HIV gp160 vaccine on monokine production.

Pneumococcal vaccination in people living with HIV.

Artificial viral envelopes containing recombinant human immunodeficiency virus (HIV) gp160.

Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.

Convergent evolution in the homology between HIV gp160 and HLA class II molecules.

gp160 of HIV-I synthesized by persistently infected Molt-3 cells is terminally glycosylated: evidence that cleavage of gp160 occurs subsequent to oligosaccharide processing.

Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160.

Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.

Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160.

Properties of HIV membrane reconstituted from its recombinant gp160 envelope glycoprotein.

HIV false positivity after hepatitis B vaccination.

II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.

Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.

Developments in HIV-1 immunotherapy and therapeutic vaccination.

BCG vaccination induces HIV target cell activation in HIV-exposed infants in a randomized trial.

Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.

Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine.

Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection.

Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.

Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United States.

Effectiveness of UNAIDS targets and HIV vaccination across 127 countries.

Suggest Documents

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2.

Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients.

Effect of a recombinant HIV gp160 vaccine on monokine production.

Pneumococcal vaccination in people living with HIV.

Artificial viral envelopes containing recombinant human immunodeficiency virus (HIV) gp160.

Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.

Convergent evolution in the homology between HIV gp160 and HLA class II molecules.

gp160 of HIV-I synthesized by persistently infected Molt-3 cells is terminally glycosylated: evidence that cleavage of gp160 occurs subsequent to oligosaccharide processing.

Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160.

Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.

Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160.

Properties of HIV membrane reconstituted from its recombinant gp160 envelope glycoprotein.

HIV false positivity after hepatitis B vaccination.

II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.

Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.

Developments in HIV-1 immunotherapy and therapeutic vaccination.

BCG vaccination induces HIV target cell activation in HIV-exposed infants in a randomized trial.

Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.

Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine.

Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection.

Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.

Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United States.

Effectiveness of UNAIDS targets and HIV vaccination across 127 countries.

Vaccination with gp160 in HIV.

Recommend Documents

Follow Us